AFM13: A First-In-Class Tetravalent Bispecific Anti-CD30/CD16A Antibody for NK Cell-Mediated Immunotherapy

Authors

Jingjing Wu, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jiaping Fu, Department of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
Mingzhi Zhang, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Delong Liu, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. DELONG_LIU@NYMC.EDU.

Author Type(s)

Faculty

DOI

10.1186/s13045-015-0188-3

Journal Title

Journal of Hematology & Oncology

First Page

96

Document Type

Article

Publication Date

8-1-2015

Abstract

Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.

Recommended Citation

Wu, J., Fu, J., Zhang, M., & Liu, D. (2015). AFM13: A First-In-Class Tetravalent Bispecific Anti-CD30/CD16A Antibody for NK Cell-Mediated Immunotherapy. Journal of Hematology & Oncology, 8, 96. https://doi.org/10.1186/s13045-015-0188-3